Bank of New York Mellon Corp reduced its stake in shares of Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) by 16.3% during the second quarter, Holdings Channel reports. The fund owned 187,741 shares of the company’s stock after selling 36,440 shares during the period. Bank of New York Mellon Corp owned approximately 0.99% of Enanta Pharmaceuticals worth $4,140,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of the stock. Adams Diversified Equity Fund Inc. purchased a new stake in shares of Enanta Pharmaceuticals during the second quarter valued at about $194,000. Pacad Investment Ltd. raised its stake in shares of Enanta Pharmaceuticals by 15.3% in the first quarter. Pacad Investment Ltd. now owns 9,800 shares of the company’s stock valued at $288,000 after buying an additional 1,300 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Enanta Pharmaceuticals during the first quarter valued at about $356,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Enanta Pharmaceuticals during the first quarter valued at about $411,000. Finally, Virginia Retirement System purchased a new stake in shares of Enanta Pharmaceuticals during the first quarter valued at about $540,000. Hedge funds and other institutional investors own 70.82% of the company’s stock.
Shares of Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) traded up 1.11% during trading on Tuesday, hitting $26.44. The stock had a trading volume of 193,136 shares. The stock’s 50-day moving average price is $23.58 and its 200 day moving average price is $24.97. Enanta Pharmaceuticals Inc. has a 1-year low of $16.75 and a 1-year high of $41.77. The firm has a market capitalization of $503.29 million, a P/E ratio of 17.49 and a beta of 0.58.
Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, August 8th. The company reported ($0.06) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.03. The business had revenue of $14 million for the quarter, compared to analysts’ expectations of $13.07 million. Enanta Pharmaceuticals had a return on equity of 11.31% and a net margin of 32.59%. The business’s quarterly revenue was up 20.7% on a year-over-year basis. During the same period last year, the firm earned $0.13 earnings per share. On average, analysts anticipate that Enanta Pharmaceuticals Inc. will post $1.02 earnings per share for the current year.
Several brokerages have issued reports on ENTA. Zacks Investment Research lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, July 28th. JPMorgan Chase & Co. set a $26.00 price target on Enanta Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $26.58.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc. (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.